

contd
a2

Claim 57. (Amended) A pharmaceutical composition comprising a compound of claim 71 and a physiologically acceptable carrier.

Claim 58. (Amended) A pharmaceutical composition comprising a compound of claim 72 and a physiologically acceptable carrier.

Claim 59. (Amended) A pharmaceutical composition comprising a compound of claim 73 and a physiologically acceptable carrier.

Please add new claims 68-98 as follows.

a3

--68. A compound selected from the group consisting of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

69. The compound

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

contd.
a3

70. The compound

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

71. The compound

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

72. The compound

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

73. The compound

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

74. A method for the treatment of a cancerous cell growth mediated by RAF kinase comprising administering a compound selected from the group consisting of:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea,

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea;

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

75. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(5-*tert*-butyl-2-methoxy phenyl)-*N'*-(4-(4-methoxy-3-(*N*-methylcarbamoyl)phenoxy)phenyl) urea.

contd.
a³

76. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

77. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea.

78. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

79. A method for the treatment of a cancerous cell growth as in claim 74 mediated by RAF kinase comprising administering:

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.

80. A method as in claim 79 for the treatment of solid cancers.

81. A method as in claim 74 for the treatment of carcinomas, myleoid disorders or adenomas.

82. A method as in claim 75 for the treatment of carcinomas, myleoid disorders or adenomas.

83. A method as in claim 76 for the treatment of carcinomas, myleoid disorders or adenomas.

84. A method as in claim 77 for the treatment of carcinomas, myleoid disorders or adenomas.

85. A method as in claim 78 for the treatment of carcinomas, myleoid disorders or adenomas.

contd.
a³

86. A method as in claim 79 for the treatment of carcinomas, myleoid disorders or adenomas.

87. A method as in claim 74 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

88. A method as in claim 75 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

89. A method as in claim 76 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

90. A method as in claim 77 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

91. A method as in claim 78 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

92. A method as in claim 79 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

93. A method as in claim 74 for the treatment of myeloid leukemia or villous colon adenomas.

94. A method as in claim 75 for the treatment of myeloid leukemia or villous colon adenomas.

95. A method as in claim 76 for the treatment of myeloid leukemia or villous colon adenomas.

96. A method as in claim 77 for the treatment of myeloid leukemia or villous colon adenomas.

contd.
*a*³

97. A method as in claim 78 for the treatment of myeloid leukemia or villous colon adenomas.

98. A method as in claim 79 for the treatment of myeloid leukemia or villous colon adenomas.--
